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Abstract
Nearly half of bladder cancer patients experience recurrences. Reliable predictors of this recurrent 
phenotype are needed to guide surveillance and treatment.
Objective—To identify genetic variants that modify bladder cancer prognosis focusing on genes 
involved in major biological carcinogenesis processes (apoptosis, proliferation, DNA repair, 
hormone regulation, immune surveillance, and cellular metabolism).
Subjects and methods—We analyzed variant genotypes hypothesized to modify these 
processes in 563 urothelial-cell carcinoma cases enrolled in a population-based study of incident 
bladder cancer conducted in New Hampshire, U.S.A.
After diagnosis, cases were followed over time to ascertain recurrence and survival status, making 
this one of the first population-based studies with detailed prognosis data.
Cox proportional hazards regression was used to assess the relationship between SNPs and 
prognosis endpoints.
Results—Aldehyde dehydrogenase 2 (ALDH2) variants had shorter time to first bladder cancer 
recurrence (adjusted non-invasive HR 1.90 95%CI 1.29-2.78).
We observed longer survival among bladder cancer cases with non-invasive tumors associated 
with DNA repair XRCC4 heterozygous genotype compared with wildtype (adjusted HR 0.53 
95%CI 0.38-0.74).
Time to recurrence was shorter for patients who had a variant allele in vascular cellular adhesion 
molecule 1 (VCAM1) and were treated with immunotherapy (P interaction <0.001).
Conclusion—Our analysis suggests candidate prognostic SNPs that could guide personalized 
bladder cancer surveillance and treatment.
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Introduction
In the Western world, bladder cancer is the fourth most common cancer in men, and eighth 
most common in women [1]. Bladder cancer generally carries a favorable prognosis, but 
rates of recurrent disease are high, with over 40% having a recurrence in some form [2]. 
Bladder cancer is among the most expensive malignancies to treat due to the need for 
frequent, painful screening procedures to identify recurrences [3, 4]. Predictors of recurrent 
bladder cancer include tumor multiplicity, tumor size, T category, presence of carcinoma in 
situ, tumor grade, and patient gender [5]. Refining our ability to identify those patients at 
high-risk of recurrent disease for more frequent screening and aggressive treatment could 
help to improve quality of life for all bladder cancer patients [4].
Genetic variations in prognosis and response to treatment have been observed for many 
cancers [6]. A number of different mechanisms have adapted to respond to specific types of 
exogenous damage or aberrant cellular behavior to prevent or repair damage to 
macromolecules, and to remove damaged cells. We hypothesized that bladder cancer 
prognosis may be affected by genetic variation in each of these major carcinogenesis 
mechanisms. We tested whether genetic variation in each of these major processes 
dysregulated in carcinogenesis that could modify bladder cancer prognosis: apoptosis, DNA 
repair, hormone, immune surveillance, metabolism, proliferation, neural, telomere, and 
transport. Our study is the first population-based bladder cancer study in the U.S. with long-
term case follow-up for recurrence. We performed analyses of hypothesized prognosis-
related SNPs by carcinogenesis process, and identified interactions and sets of genes.
Subjects and Methods
Study group
We identified all cases of bladder cancer among New Hampshire residents, ages 25 to 74 
years, in two sequential phases based on cancer diagnosis date (Phase I 1 July 1994–30 June 
1998, Phase II 1 July 1998–30 June 2001) from the New Hampshire State Cancer Registry. 
Detailed methods have been described previously [16, 17]. Briefly, we interviewed a total of 
857 bladder cancer cases, which was 85% of the cases confirmed to be eligible for the study. 
Slides and blocks were re-reviewed by the study pathologist to assess tumor histology, stage 
and grade using both the 1973 and 2004 WHO classifications of bladder tumors. The stage 
assigned by the pathologist was used for tumors <stage 2A, while Cancer Registry data on 
stage was used for higher stage. After re-review, 21 were non-cancer and 7 undetermined, 
leaving n=829 tumors which were either deemed cancerous by histopathology re-review 
(~90%), or the original diagnosis if the pathology materials were unavailable. The histologic 
composition of these tumors was 817 urothelial-cell (transitional-cell) carcinoma (660 
papillary urothelial cell carcinoma, 133 urothelial cell carcinoma, 4 papillary carcinoma, 20 
carcinoma NOS), as well as 2 spindle cell carcinoma, 3 small cell carcinoma, 5 squamous 
Andrew et al. Page 2













cell carcinoma, 2 adenocarcinoma. We omitted n=9 participants with primary diagnosis 
dates >2 years prior to the diagnosis date assumed in the interview. Most (>95%) of the 
subjects in this study are of self-reported Caucasian origin; thus restricting our genetic 
analyses to n=786 Caucasians did not appreciably alter the results. Analyses were further 
restricted to cases with known tumor stage (omitting n=3), leaving a total of n=783 
participants in the analysis.
Personal interview
Informed consent was obtained from each participant and all procedures and study materials 
were approved by the Committee for the Protection of Human Subjects at Dartmouth 
College (approved study registration number: 11697). Consenting participants underwent a 
detailed in-person interview, usually at their home.
Disease status and the main objectives of the study were not disclosed to the interviewers. 
To ensure consistent quality of the study interviewer, interviews were tape recorded with the 
consent of the participants and routinely monitored by the interviewer supervisor. Subjects 
were asked to provide a blood sample (buccal sample was requested in the case of a refusal). 
Samples were maintained at 4°C and sent via courier to the study laboratory at Dartmouth 
within 24 hours for processing and analysis.
Genotyping
DNA was isolated using Qiagen genomic DNA extraction kits (QIAGEN Inc., Valencia, 
CA) from peripheral circulating blood lymphocyte specimens harvested at the time of 
interview. Genotyping was performed on all DNA samples of sufficient concentration 
(representing n=563 of the urothelial cell carcinoma cases in the analytic dataset), using the 
GoldenGate Assay system (Illumina, Inc., San Diego, CA). Genotyped SNPs were mostly 
those included on the Illumina Cancer Panel (1,421 SNPs in approximately 400 
hypothesized cancer-related genes) (Supplementary Table I). SNPs were selected within 
coding, intronic and flanking regions hypothesized to be potentially functional of the genes 
of interest, including a median of 3 SNPs per gene. Results reported were restricted to SNPs 
with a minimum minor allele frequency of 5% and genotype call data available on at least 
90% of our samples (n=1,367 SNPs). Samples repeated on multiple GoldenGate plates 
yielded the same call for 99.9% of SNPs and 99.5% of samples submitted were successfully 
genotyped.
The main goal of the statistical analysis was to assess the relationship between genetic 
variation in nine major carcinogenesis processes and bladder cancer susceptibility and 
prognosis. These nine processes are: Apoptosis, DNA Repair, Immune, Hormone, 
Metabolism, Neural, Proliferation, Telomere, and Transport or Signaling. We grouped SNPs 
that were involved in each process according to the Database for Annotation, Visualization, 
and Integrated Discovery (DAVID) Gene Ontology (GO) search engine [18]. The number of 
SNPs analyzed by functional group was: (metabolism n=340, proliferation n=304, immune 
n=243, DNA repair n=224, transport / signaling n=170, apoptosis n=135, hormone n=68, 
telomere n=27, neural n=11) (see full SNP list in Supplemental Table I).
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Information on bladder cancer recurrences was obtained from medical records provided by 
the treating hospital(s) (both in and outpatient records, including any pathology reports) 
covering the follow-up period. Records were reviewed by an experienced, certified tumor 
registrar to abstract the data on bladder tumors occurring subsequent to the incident tumor. 
Hospital registry data were used if the medical record could not be obtained. The first 
recurrent tumor was defined as any tumor identified a disease-free remission period, more 
than 90 days after the date of initial primary bladder tumor diagnosis. These recurrent 
tumors include those of the same level of invasiveness, as well as those which have 
progressed to higher stage/grade. Persistent primary tumors that did not have a remission 
period are excluded from the analysis of recurrence (n=7). Time to recurrence was 
calculated as the time between the initial diagnosis date and the date of the first recurrence 
event. For progression analysis, the diagnosis of a tumor with a greater stage or grade than 
the initial primary bladder tumor was considered the event. If no events were reported, the 
patient was last seen documented in the medical record was used for censoring. Status (alive 
or dead) was determined as of January 13, 2011 using the Social Security and the National 
Death Indices (NDI). Survival time was calculated from the date of initial diagnosis to date 
of death. Data on the initial course of treatment were obtained from the State Cancer 
Registry and were verified by medical record review (immunotherapy 13.4%, chemotherapy 
1.7%, radiotherapy 0.4%, transurethral resection 88.5%, cystectomy 2.1%). Analyses of 
genetic variation in relation to prognosis were restricted to the urothelial-cell carcinomas 
with genotype data available (n=563).
Statistical analysis
Bladder cancer prognosis associated with the individual SNPs was analyzed separately 
within each of the five biologic pathways of interest. Median times to first recurrence or 
death were calculated using the Kaplan-Meier method. Time to the first bladder tumor 
recurrence and survival analyses were performed using Cox-proportional hazards regression 
analysis in SAS version 9.3. Analyses were performed overall, and then separately for non-
invasive tumors (stage 0, I), and invasive tumors (stage II, III, IV). The standard prognostic 
model included adjustment for age at diagnosis, gender, smoking (never, former, 
continuing), as well as tumor size (<3cm, ≥3cm), and multiplicity (single, >1) low grade, 
high grade, presence of Cis, and treatment (immunotherapy, chemotherapy, radiotherapy, 
transurethral resection, cystectomy). P values represent two-sided statistical tests. To correct 
for multiple comparisons within each group of SNPs, we also calculated P-values adjusted 
for the False Discovery Rate (FDR) for the total number of SNPs within a functional group. 
We report SNPs with FDR adjusted P-values <0.25. Statistical significance was considered 
at P<0.001 and we restricted our report to SNPs that also meet this cutoff. Kaplan-meier 
plots were examined and reported results are restricted to those with hazards that are 
proportional. To avoid reporting unstable estimates, we set the minimum cell size to n=20 
for the main effects reported. Hardy-Weinberg equilibrium testing was performed by 
comparing the observed genotype distribution in the participants to that expected for a 
population in equilibrium (freq A = p; freq a = q; p + q = 1, freq AA = p2, freq Aa = 2pq, 
freq aa= q2) using a Chi-square test. We performed an a priori assessment of power for 
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these analyses using a range of conservative Bonferroni corrected P-values (0.05/number of 
SNPs interrogated per pathway), which resulted in alphas ranging from 0.005 – 0.0001. 
With a variant SNP prevalence of 33%, we estimate 80% power to detect a minimum HR of 
1.6 with n=520 patients with alpha=0.005, while we could detect a minimum HR of 1.85 
with n=540 for an alpha=0.0001.
We constructed receiver operating characteristic curves and calculated the area under the 
curve (AUC) to evaluate the specificity and sensitivity of predicting 5-year recurrence and 
10-year survival. Patients not experiencing the endpoint within the time interval were 
omitted from the model. Interactions between SNPs in relation to the time-to-event 
endpoints recurrence and survival were detected using our Survival - Multifactor 
Dimensionality Reduction (Surv-MDR) algorithms run in R 2.6.1 [19]. This method 
modifies the nonparametric multifactor dimensionality reduction (MDR) constructive 
induction algorithm to use the log-rank test. We ran MDR separately on each functional 
group of SNPs and selected the best SNP-SNP MDR model as the one with the lowest 
average prediction error. An error rate of 50% is expected under the null hypothesis. 
Statistical significance is determined using permutation testing. Here, the case-control labels 
are randomized 1000 times and the entire MDR model fitting procedure repeated on each 
randomized dataset to determine the expected distribution of testing accuracies under the 
null hypothesis. We used 10-fold cross-validation and 1000-fold permutation testing to 
reduce the chances of making a type I error due to multiple testing [20, 21].
To evaluate the multiplicative vs. additive nature of the interactions between the SNP allele 
combinations predicted by Surv-MDR, we included interaction terms in a Cox-proportional 
hazards model with adjustment for age at diagnosis, gender, smoking (never, former, 
current), as well as tumor size (<3cm, ≥3cm), and multiplicity (single, >1), low grade, high 
grade, presence of carcinoma in situ (Cis), and treatment (immunotherapy, chemotherapy, 
radiotherapy, transurethral resection, cystectomy). As the number of invasive cases was 
small in this population-based study, we analyzed of recurrence and survival interactions 
within the non-invasive cases only.
The Gene Set Analysis (GSA) method was performed in R version 2.7.2 to assess the 
significance of the each of the functional groups in relation to the time-to-event endpoints. 
GSA ranks the SNPs by their correlation with the endpoint (positive for decreased risk, 
negative for increased risk). An enrichment score is calculated as a running-sum statistic that 
increases when the next SNP down the list is in the same functional group, but decreases 
when it is not. Thus, enrichment scores with the maximum deviation from zero are achieved 
when multiple SNPs of the same functional group are ranked close together at the very top 
or bottom of the ranked correlation list. The peak enrichment score is the highest positive 
score, indicating that the variant form of the SNP is protective, or the lowest negative score, 
indicating that the variant form of the SNP is a risk factor. The False Discovery Rate (FDR) 
is then calculated using 1000 permutations of the endpoint to estimate the probability that 
the enrichment score represents a false positive finding. The enrichment score for GSA is a 
“maxmean” statistic, computed by averaging the positive parts of each Z-score in a given 
pathway, as well as the negative parts. We choose the Z-score that is larger in absolute 
value. GSA uses permutation testing to determine the P-value. Using these methods, we first 
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analyzed the SNPs broken into nine major carcinogenesis pathways: apoptosis, DNA repair, 
hormone, immune surveillance, metabolism, proliferation, neural, telomere, and transport. 
We also applied a highly detailed assessment of SNPs grouped into 600 Gene Ontology 
(GO) biological processes using the Pathway Studio ResNet 8 database (Ariadne 
Genomics).
Results
Then genotyped population had similar characteristics as the overall case group (Table 1). 
As our study is population-based and included both community and academic facilities 
throughout the state, the majority (84%) of our cases were non-muscle invasive at initial 
diagnosis. Medical data were reviewed on 94% of the cases, with a median duration of 
follow-up of 5.4 years and 75% of the cases were followed >1.6 years. Half of the cases 
experienced at least one recurrence during the follow-up period and 40% were deceased 
(Table 1). Hardy Weinberg equilibrium P-values of the prognosis-associated SNPs in the 
bladder cancer case population were (ALDH2_08 rs2238151 0.32, IGF1_24 rs5742714 
0.04, XRCC4_07 rs2662238 0.28, DRD4_15 rs4987059 0.35, RB1CC1_50 rs35402311 
0.76, IL15RA_04 rs2228059 0.87, MBL2 rs2099902 0.06, TNKS_03 rs34206126 0.15, 
APC_09 rs2229992 0.76, VCAM1_05 rs3176879 0.05, IL1B_01 rs16944 0.70, IFNG_07 
rs1861494 0.61).
Within each of the nine major carcinogenesis processes, relationships between SNPs and 
bladder cancer recurrence or survival were assessed using Cox regression with adjustment 
for age, gender, smoking, stage, grade, treatment. Assuming incomplete dominance, we 
tested heterozygous vs. wildtype; variant vs. wildtype. The variant form of metabolism SNP 
ALDH2 rs2238151 in Aldehyde Dehydrogenase was associated with a shorter time to 
recurrence (overall HR 2.03, FDR adjusted P-value <0.001) (Table 2, Figure 1a). Because 
alcohol metabolism is a major role of ALDH2, we investigated the possibility that this SNP 
modified the effect of alcohol exposure. We observed an interaction between ALDH2 
rs2238151 variant genotype and drinking at least 31 alcoholic drinks per month during the 
5-year period prior to diagnosis, compared to never drinkers (interaction P value 0.011). 
Among ALDH2 variants, drinking alcohol over the 5 years prior to diagnosis lowered the 
risk of recurrence compared to never drinking (HR 0.11 95%CI 0.031 – 0.38). Restricting to 
those who did not consume alcohol, ALDH2 variant genotype was associated with increased 
risk of recurrence compared to wildtype, however the confidence intervals were imprecise 
(HR 12.89 95%CI 4.00-41.49).
For non-invasive bladder cancer cases, participants with the heterozygous form of 
proliferation SNP IGF1 rs5742714 in Insulin-like Growth Factor 1 had shorter time to 
recurrence compared with wildtype (HR 1.61, FDR 0.20) (Table 2, Figure 1b). Despite 
limited statistical power, we also evaluated the recurrence – associated main effect SNPs in 
relation to tumor progression. IGF1 rs5742714 heterozygotes showed a non-significant trend 
towards an increased risk of tumor progression compared to wildtype (adjusted HR 2.24 
95%CI 0.83-6.05).
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Table 3 shows the survival – associated SNPs based on analysis of the time from the initial 
bladder cancer diagnosis to death or censoring. For non-invasive cases, the double-strand 
DNA repair SNP XRCC4 rs2662238 was associated with longer survival among 
heterozygotes (HR 0.52, FDR <0.001) (Figure 2a). Heterozygotes for neural SNP in the 
dopamine receptor D4 DRD4 rs4987059 had shorter survival times (HR 1.83, FDR 0.02) 
(Figure 2b). A SNP in the proliferation pathway RB1-inducible coiled-coil 1 gene (RB1CC1 
rs35402311) conferred shorter survival overall (HR 2.29 FDR <0.001) and for both non-
invasive (HR 2.13) and invasive cancers (HR 3.86) (Figure 2c).
We also ran ‘Surv-MDR’ algorithms to detect potential gene-gene interactions in time-to-
event data using log-rank statistics [19]. We ranked the two SNP model combinations within 
each of the major carcinogenesis processes in relation to recurrence and survival of non-
invasive bladder cancer cases. Cox-regression analysis confirmed a multiplicative 
interaction for recurrence between the top model, including the variant forms of immune 
genes IL15RA rs2228059 and MBL2 rs2099902 heterozygosity (interaction P<0.0001) 
(Table 4). For survival, the combination of proliferation SNPs TNKS rs34206126 
heterozygous/variant and APC rs2229992 heterozygous/variant showed a multiplicative 
association by Cox-regression analysis (interaction P=0.001) (Table 4).
Receiver operating characteristic curves demonstrate the predictive value of the models with 
and without the inclusion of SNP genotype. In Figure 4, the blue line shows the area under 
the curve (AUC) for the ‘Base’ models containing age, gender, smoking, stage, grade, 
treatment for non-muscle invasive urothelial cell carcinoma recurrence (Fig 4a,) and 
survival (Fig 4b). The addition of genotype parameters for ALDH2 rs2238151, IGF1 
rs5742714, and IL15RA rs2228059 / MBL2 rs2099902 significantly improved the 
prediction of 5-year recurrence (AUC 0.71 to 0.75, chi-square P =0.02). Likewise, the AUC 
for 10-year survival went from 0.76 to 0.80 with the addition of SNP information for 
XRCC4 rs2662238 DRD4 rs4987059 RB1CC1 rs35402311 TNKS rs34206126*APC 
rs2229992 (P =0.008).
We then assessed the SNPs grouped into sets using Gene Set Enrichment Analysis. Using 
the nine major carcinogenesis pathway groups, we observed enrichment scores indicating 
shorter time to bladder cancer recurrence with the variant form of ‘immune response’ gene 
SNPs (FDR 0.06) and longer time to recurrence with ‘hormone regulation’ variant gene 
SNPs (FDR 0.11) (Table 5). We also tested for enrichment of the 600 GeneOntology (GO) 
Biological Processes in relation to recurrence and survival, however all FDR adjusted p-
values exceeded 0.25.
We then tested the hypothesis that the effectiveness of immunotherapy treatment would be 
modified by SNPs in immune-related genes. We performed likelihood ratio testing for 
interactions between immune-related SNPs and immunotherapy in relation to recurrence and 
survival. The lowest interaction P-values was observed for VCAM1 rs3176879 
heterozygous or variant genotype shortening time to recurrence for cases receiving 
immunotherapy treatment (interaction P<0.001, FDR 0.06) (Table 6). There was also a 
three-way multiplicative interaction between IL1B rs16944, IFNG_07 rs1861494 variant 
alleles and immunotherapy treatment (interaction P=0.003, HRs with immunotherapy: IL1B 
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GG vs. GA/AA 0.34 (95%CI 0.17- 0.71), IFNG TT vs. TC/CC 0.40 (95%CI 0.22 - 0.75)), 
with longer time to recurrence for immunotherapy treated patients who were carriers of at 
least one variant allele for both genes (median recurrence time 9.76 years), compared to 
patients who were wildtype for both genes (median time to recurrence 1.30 years).
Analyses of the prognostic SNPs within each of the cohorts of bladder cancer patients 
separately demonstrate concordant results across the two different New Hampshire 
populations. Study phase I included n=303 genotyped patients, while study phase II included 
n=260. For recurrence for non-muscle invasive urothelial tumors, adjusted HRs were: 
ALDH_02 var., phase I HR 1.61 95%CI 0.93-2.78, phase II 2.58 95%CI 1.47-4.53; IGF1 
rs5742714 het. Phase I HR 1.80 95%CI 1.16-2.80, phase II HR 1.78 95%CI 1.13-2.80). For 
survival, adjusted HRs were: XRCC4 rs2662238 het., phase I 0.48 95%CI 0.31-7.4, phase II 
0.62 95%CI 0.34-1.12; DRD4 rs4987059 het. phase I HR 2.06 95%CI 1.16-3.68. phase II 
HR 1.52 95%CI 0.72-3.22; RB1CC1 rs35402311 het phase I HR 2.68 95%CI 1.42-5.04, 
phase II HR 1.44 95%CI 0.70-2.99. The interaction P-values were: phase I P<0.0001, phase 
II P=0.008 for IL15RA rs2228059/MBL2 rs2099902; phase I P=0.02, phase II P=0.01 
TNKS rs34206126/APC rs2229992.
Discussion
We observed that genetic variations impacting several major carcinogenesis processes 
modified time to bladder cancer recurrence, progression and length of survival. We also 
identified SNP-SNP and SNP-treatment interactions significantly associated with these 
events. To our knowledge, our unique study has one of the only population-based datasets 
with detailed follow-up of patients for bladder cancer recurrence and survival information in 
the U.S.
We observed a higher rate of recurrence associated with variants in the Aldehyde 
dehydrogenase (ALDH2) enzyme, which performs oxidative catalysis of alcohol. ALDH2 
SNPs have been associated with higher levels of smoking-DNA adducts in blood [22], with 
higher rates of esophageal cancer [23] and with lung cancer in smokers [24], possibly 
involving the DNA damaging effects of acetaldehyde [25]. Among cases with the variant 
ALDH2 rs2238151 genotype, alcohol consumption was associated with a longer time to 
tumor recurrence, possibly due to decreased enzymatic activity, which reduces formation of 
reactive intermediates. Treatment with the ALDH2 inhibitor, Disulfiram, lowers bladder 
cancer risk in rats exposed to nitrosamines, because the inhibitor prevents ALDH2 from 
converting the chemicals into reactive intermediates that are excreted through the bladder 
[26] (Suppl. Figure 4a).
We also observed a shorter time to first recurrence associated with a cell proliferation – 
related polymorphism in the Insulin-like Growth Factor 1 (IGF1). IGF1 activates AKT 
signaling to promote cell cycle, proliferation and inhibit apoptosis. The same SNP that we 
observed (rs5742714 C/G) in the 3’UTR was associated with survival for non-small cell 
lung cancer cases [27]. SNPs in this 3’UTR region could function by disrupting binding of a 
microRNA. IGF1 is a target of miR-1 and miR-206 [28] (Suppl. Figure 4b).
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In the DNA repair pathway, heterozygotes for SNP rs2662238 in X-ray repair cross-
complementing protein 4 (XRCC4) experienced longer survival. XRCC4 is involved in the 
ligation step of DNA double-strand break by non-homologous end joining (Suppl. Figure 
4c). While XRCC4 SNPs have previously been associated with increased bladder cancer 
risk, our study is the first to report a relationship with prognosis. SNPs identified in prior 
studies of bladder cancer incidence include the XRCC4 SNP G-1394T rs6869366 in a 
Taiwanese study of n=158 cases and controls (low LD with XRCC4 rs2662238: R2 0.019) 
[29], intron 7 SNP rs1805377 in a Spanish study of 1150 cases and controls [30], and in 211 
cases, 250 controls in North India and (low LD with XRCC4 rs2662238: R2 0.005) [31]. 
The observed contrast (increasing cancer risk, but lowering survival time) may be explained 
by compromised repair of DNA promoting mutations in tumor suppressor genes. Once a 
tumor has formed, however, it is conceivable that tumor cells with damaged DNA are more 
easily recognized for elimination by immunoediting machinery and compromised DNA 
repair increases chemotherapy efficacy, as observed for cisplatin treatment of lung cancer 
[32].
We also found an association between heterozygous genotype for the dopamine receptor D4 
(DRD4) and 2-fold shorter survival. DRD4 polymorphisms are associated with increased 
novelty seeking behavior, including a propensity to take up smoking as an adolescent and 
with a higher intensity of smoking overall [33, 34].
RB1CC1 rs35402311 in the 5’ region near the RB1-inducible coiled-coil 1 gene was also 
associated with a 2.29 fold shorter survival time. RB1CC1 is a tumor suppressive 
transcription factor that regulates cell growth, cell proliferation, as well as apoptosis and cell 
migration by controlling RB1 (retinoblastoma 1) expression. RB1CC1 binds and stabilizes 
the tumor suppressor p53, is mutated in tumors, and was associated with multi-drug 
resistance to chemotherapy agents [35] (Suppl. Figure 4d).
Survival was lengthened for cases with variant forms of Wnt pathway regulators Tankyrase 
(TNKS) and Adenomatous polyposis coli (APC) gene, which is mutated in colon cancers. 
APC normally holds the cell cycle promoting transcription factor B-catenin in a proteolytic 
degradation complex, keeping levels low, however APC alterations compromise this control 
[36] (Suppl. Figure 4e). Tankyrase (TNKS) is a poly-ADP ribosylase that normally degrades 
Axin. Inhibiting TNKS stabilizes Axin, facilitating degradation of B-catenin, and preventing 
stem cell proliferation [37]. Levels of TNKS mRNA in urine are associated with bladder 
cancer recurrence [38]. The combination of TNKS and APC variations that both increase B-
catenin degradation would block proliferation.
The Gene Set Enrichment Analysis identified clusters of SNPs related to longer time to 
recurrence in the ‘hormone’ and ‘immune’ sets. The predominance of bladder cancer in 
males, as well as other studies implicate a specific role for androgens and the androgen 
receptor in bladder cancer [40]. In the immune set, a SNP in the cytokine receptor antagonist 
IL15RA interacted with a SNP in mannose-binding lectin (protein C) 2 (MBL2) to increase 
bladder cancer recurrence rates (HR 4.32). MBL2 activates the complement pathway when 
it recognizes mannose and N-acetylglucosamine on microorganisms and also activates 
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macrophages to destroy late apoptotic cells. MBL SNPs were previously associated with 
lung cancer survival [41].
We specifically hypothesized that immune response genotypes would modify the response 
to immunotherapy treatment. In a study of 99 patients randomized to several different BCG 
immunotherapy regimens, Chiong et al. found shorter time to bladder cancer recurrence 
associated with SNPs in the natural resistance-associated macrophage protein 1 (NRAMP1) 
gene{Chiong, 2011 #8867}. We observed a higher risk of recurrence among vascular cell 
adhesion molecule 1 (VCAM1) heterozygous or variant patients who received 
immunotherapy treatment (HR 5.0). VCAM1 is a cell surface glycoprotein involved in the 
development of lymphoid tissues. BCG treatment upregulated VCAM1 in mouse bladder 
tissue. VCAM1 upregulation could also increase lymphangiogenesis in the bladder [42].
The population-based nature of this study is an advantage for the potential generalizability 
of the results, allowing us to investigate genetic variations in relation to recurrence of non-
muscle invasive lesions. Limitations include small numbers of highly invasive lesions and 
the possibility of false positive results. We have used the FDR method to reduce the false 
positive findings associated with statistical comparisons across many SNPs and also looked 
at the consistency of our results across two subsequent cohorts. Replication studies in other 
population-based studies of non-muscle invasive tumor recurrence are needed.
Our data suggest novel associations between SNPs and bladder cancer recurrence that merit 
future investigation. Prognostic variations will help identify sub-groups of bladder cancer 
cases at high risk of tumor recurrence and progression for more intensive tumor surveillance 
and targeted treatment regimens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Bladder cancer recurrence by SNP genotype. Kaplan-Meier plots depict the percent of 
patients by the time to their first bladder cancer recurrence in years. Shaded lines separate 
patients by genotype for a) ALDH2 rs2238151 among all patients, logrank P=0.0001 b) 
IGF1 rs5742714 among all patients, log-rank P=0.0018. Vertical hatches represent 
censoring due to death or end of follow-up period.
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Bladder cancer survival by SNP genotype. Kaplan-Meier plots depict the percent of patients 
by the time to death in years. Shaded lines separate patients by genotype for a) XRCC4 
rs2662238 restricted to patients with non- invasive tumors, logrank P=0.018, b) DRD4 
rs4987059, restricted to patients with non- invasive tumors, log-rank P=0.041, and c) 
RB1CC1 rs35402311 among all patients, log-rank P=0.001. Vertical hatches represent 
censoring due to end of follow-up period.
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Bladder cancer prognosis by SNP genotype combination. Kaplan-Meier plots depict the 
percent of patients by the time to recurrence or death in years. Shaded lines separate patients 
with non-invasive tumors by genotype for a) IL15RA rs2228059/ MBL2 rs2099902 in 
relation to recurrence, log-rank P=0.05 and b) TNKS rs34206126/ APC rs2229992 in 
relation to survival, log-rank P=0.016. Vertical hatches represent censoring due to end of 
follow-up period.
Andrew et al. Page 16
BJU Int. Author manuscript; available in PMC 2016 February 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
